|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-8-6
|
|
pubmed:abstractText |
Incorporating topotecan into standard platinum/taxane chemotherapy for advanced ovarian cancer has been complicated by myelosuppression. This study evaluated sequential doublets of topotecan and carboplatin, followed by paclitaxel and carboplatin, in newly diagnosed advanced ovarian cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
533-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15297200-Adenocarcinoma,
pubmed-meshheading:15297200-Adult,
pubmed-meshheading:15297200-Aged,
pubmed-meshheading:15297200-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15297200-CA-125 Antigen,
pubmed-meshheading:15297200-Carboplatin,
pubmed-meshheading:15297200-Cystadenocarcinoma, Papillary,
pubmed-meshheading:15297200-Cystadenocarcinoma, Serous,
pubmed-meshheading:15297200-Disease-Free Survival,
pubmed-meshheading:15297200-Drug Administration Schedule,
pubmed-meshheading:15297200-Female,
pubmed-meshheading:15297200-Humans,
pubmed-meshheading:15297200-Middle Aged,
pubmed-meshheading:15297200-Neoplasm Staging,
pubmed-meshheading:15297200-Ovarian Neoplasms,
pubmed-meshheading:15297200-Paclitaxel,
pubmed-meshheading:15297200-Peritoneal Neoplasms,
pubmed-meshheading:15297200-Topotecan
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
|
|
pubmed:affiliation |
Texas Oncology, P.A., Charles A. Sammons Cancer Center, Dallas, TX 75246, USA. agordonmd@earthlink.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
